Pacritinib is now included as a recommended treatment for myeloproliferative neoplasms with specificity for JAK2 and IRAK1 in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice ...

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests. Despite recent advancements in treatments for ...

Please provide your email address to receive an email when new articles are posted on . John O. Mascarenhas, MD, spoke with Healio about a presentation given during the morning session at 14th ...

There are promising drugs for myeloproliferative neoplasms coming down the pipeline. It is an exciting time for the treatment of myeloproliferative neoplasms (MPNs), as new treatments continue to ...

Please provide your email address to receive an email when new articles are posted on . In this video, John O. Mascarenhas, MD, provided an overview of his presentation at 14th International Congress ...

Myeloproliferative disorders (MPDs) are a group of blood cancers traditionally treated using medications, blood filtration, and chemotherapy or radiation. In recent news, several studies and clinical ...

Type I JAK2 inhibitors improve symptoms and outcomes of patients with myeloproliferative neoplasms (MPNs), but mutant allele JAK2 VF remains unchanged with this therapy. Type II JAK2 inhibitors bind ...

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest. Name recognition. The term is often associated with Fortune 500 ...

CHICAGO, Dec. 4, 2025 /PRNewswire/ -- The MPN Research Foundation, a respected and influential member of the myeloproliferative neoplasms landscape, has two abstracts accepted for presentation at the ...

CHICAGO, IL, UNITED STATES, December 14, 2022 /EINPresswire.com/ -- MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that ...